BioLineRx (NASDAQ:BLRX) Upgraded to “Sell” by StockNews.com

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX) to a sell rating in a research note released on Friday morning.

Separately, HC Wainwright reiterated a buy rating and set a $21.00 price objective on shares of BioLineRx in a research note on Tuesday, March 26th.

BioLineRx Trading Down 10.2 %

Shares of BLRX stock opened at $0.64 on Friday. The stock has a market capitalization of $51.47 million, a P/E ratio of -0.72 and a beta of 1.38. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $1.10 and its 200 day moving average is $1.36. BioLineRx has a 12-month low of $0.63 and a 12-month high of $2.53.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $0.17 million. During the same period in the prior year, the company posted ($0.09) earnings per share. Research analysts expect that BioLineRx will post -1.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BLRX. NorthRock Partners LLC purchased a new position in shares of BioLineRx during the fourth quarter valued at about $27,000. B. Riley Wealth Advisors Inc. raised its stake in BioLineRx by 88.5% during the third quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 10,000 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC bought a new position in BioLineRx during the third quarter valued at $46,000. Rathbones Group PLC bought a new position in shares of BioLineRx in the 3rd quarter valued at about $72,000. Finally, Geneos Wealth Management Inc. increased its stake in BioLineRx by 72.3% during the third quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 17,000 shares during the last quarter. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.